Galecto buys leukemia drug from Bridge Medicines, drops bone cancer asset in strategic pivot

A year after the failure of an idiopathic pulmonary fibrosis candidate sent Galecto on a search for salvation, the Boston-based biotech has decided to go all-in on oncology and liver disease—including picking up a preclinical leukemia asset and culling a bone cancer drug.